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A B S T R A C T  
Objective: To find out the effect of losartan in comparison with pioglitazone on β-Cell function in a type 2 diabetic rat 
model. 
Patients and Methods: This was a randomized control trial study and was carried out at Postgraduate Medical Institute 
(PGMI), Lahore from June to August 2011. In this study 45 Sprague-Dawley rats of 5 weeks of age were randomized 
into three groups. All the rats were fed with a high fat and sucrose diet. Pioglitazone or losartan were given along with 
this diet to the rats in-group HFD-PIO and HFD-LOS respectively, while group HFD was kept under control. Body weight 
and fasting blood glucose levels were determined weekly. At the end of 12 weeks, blood glucose and serum insulin 
levels were determined. A marker of β-cell function, HOMA-β, was also calculated. 
Results: At the end of study period, body weight, fasting blood glucose, serum insulin, and HOMA-β levels were 
significantly lower in the HFD-PIO and HFD-LOS groups as compared to the control HFD group. The difference in these 
parameters between the HFD-PIO and HFD-LOS groups was not significant. 
Conclusion: Losartan is significantly comparable to Pioglitazone in improving β-cell function. 
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I n t r o d u c t i o n  
 
Diabetes mellitus, one of the most common non-
communicable diseases has become a worldwide 
epidemic. This disease is the fourth most common cause 
of death globally and is expected to affect 450 million 
people by the year 2030.1 Insulin resistance and β-cell 
dysfunction plays a major role in the pathogenesis of type 
2 diabetes mellitus. Defects in insulin secretion 
predisposes to type 2 diabetes mellitus. Studies have 
shown that individuals genetically predisposed to develop 
type 2 diabetes mellitus, when exposed to chronically 
increased levels of free fatty acids (for example in obesity 
or due to high-fat diet) may be prone to lipotoxicity that 
results in decreased insulin secretion through beta cell 
apoptosis. The resulting hyperglycemia and decreased 
insulin leads to glucotoxicity (glucose toxicity) that further 
decreases insulin secretion and predisposes to insulin 
resistance. Lipid-induced beta-cell dysfunction may 
precede the decrease in beta cell mass.2  
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β-Cell dysfunction is a key feature of development of type 
2 diabetes mellitus.3 Drug research has focused on 
developing drugs that improve β-Cell function, including 
insulin secretagogues like the sulfonylureas and glinides, 
incretin analogs like DPP-4 inhibitors and GLP-1 analogs, 
as well as insulin itself.4 Thiazolidinediones (Glitazones) 
are a group of drugs used for treatment of type 2 diabetes 
which have shown to preserve beta cell function by 
protecting the beta-cell from lipotoxicity.  β-cell stress is 
reduced with thiazolidinedione therapy, but enhanced with 
sulfonylurea therapy.5 Thiazolidinediones mediate their 
actions through PPAR-γ receptors.  PPAR-γ activation 
acts to maintain β cell function.6 Renin angiotensin 
aldosterone system (RAAS) is also implicated in the 
development of β-Cell dysfunction. Evidence suggests 
that the RAAS affects insulin secretion. Angiotensin II 
impairs insulin biosynthesis and promotes beta cell 
apoptosis possibly due to long-term vasoconstriction-
induced restricted blood flow to the pancreas.7 
Hence, pharmacologic inhibition of this system would be 
useful in preserving beta cell function. From the present 
research point of view and the most studied among 
inhibitors of RAAS are the selective AT1 receptor blockers 
(ARBs). Development of ARBs began in 1990 with the 
synthesis of losartan, an orally active, non-peptide 
angiotensin II receptor antagonist. Since then several 
others have been synthesized including valsartan, 
irbesartan, telmisartan, candesartan, eprosartan and 
olmesartan.8 
ARBs including telmisartan, irbesartan and losartan have 
shown to possess PPAR-γ agonist activity.9 Beneficial 
effect of PPAR-γ agonist activity on improving insulin 
secretion has been mentioned. This provides a strategic 
rationale and pharmacological platform for the study of 
dual ARB/PPAR-γ agonist losartan on β-cell function in a 
rat model of β cell dysfunction. 
P a t i e n t s  a n d  M e t h o d s  
This was a randomized control trial and was carried out at 
Postgraduate Medical Institute (PGMI), Lahore. Sprague-
Dawley rats of 4 weeks of age were purchased from the 
University of Veterinary & Animal Sciences, Lahore and 
kept in the animal house of PGMI in iron cages under 
hygienic conditions. Room temperature was maintained at 
25+ 2C under natural day/night cycle with free access to 
rat chow and water. They were allowed one week to 
acclimatize. From 5 weeks of age, rats were fed on high 
fat diet containing 30% beef fat and 10% sucrose.10 
Animals were divided randomly into 3 groups of 15 
animals each. All three groups were fed with high fat and 
sucrose diet throughout study period of 12 weeks. First 
group was given distilled water daily orally as a single 
morning dose and labeled as HFD (high-fat diet) group. 
The second group was given pioglitazone in dose of 
10mg/kg body weight daily orally as a single morning 
dose for 12 weeks and labeled as HFD-PIO group.11 Third 
group was given losartan in dose of 10mg/kg body 
weight1 daily orally as a single morning dose for 12 weeks 
and labeled as HFD-LOS group.12 
Follow up 
Body Weight of Rats: Each rat was weighed initially and 
after every week. 
Measurement of Fasting Blood Glucose: Fasting blood 
glucose level was measured every week using a 
glucometer (AccuChek) using a drop of blood obtained 
from the tail vein. 
Blood Sampling: After 12 weeks, rats were kept on 12 
hours fast and blood was collected by cardiac puncture. 
Samples were then centrifuged at room temperature at 
3000-4000 rpm for 5 minutes. Serum was stored at –20°C 
until being analyzed for serum insulin determination.  
Biochemical Methods / Measurement of Serum 
Insulin: Serum insulin was estimated using insulin ELISA 
(enzyme-linked immunosorbent assay) kit 
(NovaTecImmundiagnostica GmbH).  
Calculation of Index of β Cell Function: Homestatic 
Model Assessment of β-Cell function (HOMA- β) is a 
surrogate marker of β-cell function. Many investigators 
have demonstrated strong relationships between this 
surrogate marker and responses measured with clamp 
procedure.  HOMA- β was calculated as follows.13 
HOMA- β =   360 X Insulin 
 Glucose - 63 
Drugs: Pioglitazone and losartan were obtained from 
Mass Pharmaceuticals 
The data were entered and analyzed using SPSS 17.0. 
Mean ± S.D was calculated for quantitative variables like 
fasting blood glucose levels, fasting insulin levels and 
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HOMA- β values. One-way ANOVA was applied to 
compare the above variables among the groups. Bartlett’s 
test was applied to see whether variances were 
significantly different.  
R e s u l t s  
Mean body weight at beginning of study was 82±8, 79±7 
and 81±5 g in group HFD, HFD-PIO and HFD-LOS 
respectively. The body weight increased in all groups over 
12-week study period but weight gain in rats of HFD-PIO 
and HFD-LOS group was significantly less as compared 
to those of HFD group with p-value ‹0.05. As shown in 
table 1, the difference between HFD-PIO and HFD-LOS 
group was not significant according to the  
Mean fasting blood glucose level of animals at the start of 
study was 92±9, 87±7 and 91±7 mg/dl in-group HFD, 
HFD-PIO and HFD-LOS. Fasting blood glucose level 
increased in all groups over the study period. At 12 
weeks, fasting blood glucose level was significantly less in 
HFD-PIO and HFD-LOS group as compared to that of 
HFD group with p-value < 0.001. Difference between 
HFD-PIO and HFD-LOS group was not significant (Table: 
1). 
Serum insulin level was measured at end of 12-week 
study period and it was observed that level was 
significantly lower in HFD-PIO and HFD-LOS group as 
compared to that of HFD group with p-value 0.001 and 
0.004 respectively. Difference between HFD-PIO and 
HFD-LOS group was not significant. Barlett’s test was 
applied to assess for statistical significance of these 
results (Table 1). 
HOMA-β calculated at end of study revealed significantly 
lower values in HFD-PIO and HFD-LOS group as 
compared to that of HFD control group with p-value < 
0.01 and < 0.05 respectively. (Table 1).  
D i s c u s s i o n  
In the present study, the role of losartan in improving β-
cell function was evaluated in high fat fed diabetic rats in 
comparison with pioglitazone. For this purpose, 45 
Sprague-Dawley rats of 5 weeks of age were randomized 
into three groups. All the rats were fed with a high fat and 
sucrose diet. Such an animal model is the best model to 
study the human metabolic syndrome. Numerous studies 
have shown that a diet rich in saturated fatty acids and 
refined carbohydrates increases the risk of diabetes.14 
Pioglitazone and losartan was given along with this diet to 
the rats in-groups HFD-PIO and HFD-LOS respectively, 
while group HFD was kept as control. Body weight and 
fasting blood glucose levels were determined weekly. At 
the end of 12 weeks, serum insulin levels were 
determined. A marker of β-cell function, homeostatic 
model assessment of β-cell function (HOMA-β), was also 
calculated at the end. 
Mean body weight of animals at the start of study was 
around 80 grams which increased steadily in all study 
groups during the study period but increase was more in 
HFD group as compared to HFD-LOS and HFD-PIO 
groups. As the increase in body weight is associated with 
type 2 diabetes, both groups treated with drugs along with 
a high-fat diet showed significantly less increase in body 
weight. A similar effect on body weight of rats was 
observed in one study using telmisartan and 
candesartan.15 Mean fasting blood glucose level was 
significantly low in both experimental groups as compared 
to that of control. Difference between HFD-LOS and HFD-
PIO was not significant. Chu et al also demonstrated a 
decrease in blood glucose level with losartan in a dose-
dependent manner in a genetic diabetic mice model.12 
Serum insulin levels were measured at the end of the 
study period (12 weeks) and they were found to be 
significantly raised in the HFD group as compared to 
HFD-PIO and HFD-LOS groups. Hyperinsulinemia with 
fasting and basal hyperglycemia have been observed in 
some models of type 2 diabetes due to high fat diet.10 
HOMA-β is an index of β-cell function insulin.13 Decrease 
in HOMA-β by losartan, an angiotensin receptor blocker, 
in the present study is supported by other studies on 
Table 1: Body weight and metabolic characteristics of HFD fed rats at end of 12-weeks study period 
Group Body Weight (g) 
mean + SD 
Blood Glucose (mg/dl) 
mean + SD 
Serum Insulin (µIU/ml) 
mean + SD 
HOMA-β 
mean + SD 
HFD 382 ± 48 152 ± 12 23.20 ± 5.52 89.83 ± 3.948 
HFD-PIO 345 ± 45* 123 ± 17*** 12.07 ± 6.82*** 72.47 ± 3.617** 
HFD-LOS 342 ± 38* 132 ± 17*** 14.13 ± 8.83** 66.942 ± 6.943* 
*p-value ≤ 0.05, **p- value ≤ 0.01,  *** p value ≤ 0.001 as compared to group HFD Bartlett’s test applied 
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diabetes. HOMA-β decreased in a human study with the 
use of losartan during 24 weeks follow up in 
hypertensive.17 Various other angiotensin receptor 
blockers also showed the same results. In one study, 
twenty-six weeks of treatment with valsartan increased 
glucose-stimulated insulin release and insulin sensitivity in 
normotensive subjects with impaired glucose 
metabolism.18 
Possible mechanisms of improvement of β-cell function 
by losartan include that a decrease in activity of the renin-
angiotensin aldosterone system by ARBs has been 
observed to cause significant reductions in reactive 
oxygen species, protein kinase C and NADPH oxidase 
activities in pancreatic islet cells. This has led to 
enhanced  cell survival. Increase in  cell mass also 
results from a protective effect by ARBs against harmful 
effects of inflammatory and oxidative stress. Enhanced  
cell survival & an increase in  cell mass has seen to 
increase insulin secretion and improve glucose 
tolerance.19 The primary target for insulin action & an 
important determinant of glucose uptake is skeletal 
muscle blood flow. ACE inhibitors & ARBs cause 
vasodilation in peripheral blood vessels, which leads to an 
increase in skeletal muscle blood flow. This is by 
increasing the surface area for glucose exchange 
between the vascular bed & skeletal muscles. This action 
also facilitates an increase in blood flow to the pancreatic 
islet cells, thus further increasing insulin secretion.19 
C o n c l u s i o n  
The results of present study indicate that losartan 
improves β-cell function, which is significantly comparable 
to that of pioglitazone. 
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